VisiCELL Medical provides MRI‑based in‑vivo imaging analytics that act as a “GPS for cell therapy,” giving developers actionable insights across oncology, autoimmune disease, and regenerative medicine. Its VMI‑Trac platform non‑invasively tracks therapeutic cells in real time and integrates seamlessly into existing clinical trial workflows, enabling researchers to assess treatment efficacy from preclinical studies through clinical deployment while reducing cost and improving patient outcomes.
Funding
$255.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cell‑based therapies lack reliable, non‑invasive methods to monitor the distribution, persistence, and safety of therapeutic cells in vivo, forcing developers to rely on indirect assays or invasive biopsies. This limitation slows preclinical and clinical development, increases costs, and hampers assessment of treatment efficacy for diseases such as cancer, autoimmune disorders, and regenerative indications.
Solution
VisiCELL Medical offers VMI‑Trac, an MRI‑based imaging analytics platform that provides real‑time, radiation‑free tracking of therapeutic cells throughout the preclinical‑to‑clinical continuum. By labeling cells with a proprietary nanomaterial detectable on standard clinical MRI scanners, VMI‑Trac delivers precise spatial localization and quantitative metrics without altering cell function. The platform integrates directly into existing trial workflows, supporting multi‑site studies and enabling longitudinal monitoring of cell biodistribution, viability, and safety. This data-driven insight accelerates decision‑making, reduces reliance on invasive procedures, and helps optimize dosing and delivery strategies, ultimately shortening development timelines and improving patient outcomes.
Target Audience
Primary customers are biopharmaceutical companies and academic research groups developing cell‑based therapies for oncology, autoimmune diseases, and regenerative medicine, as well as contract research organizations conducting multi‑site preclinical and clinical studies.
Features
- Nanomaterial cell labeling compatible with standard MRI sequences, providing high‑contrast, quantitative signal without radiation exposure
- Automated image processing pipeline that extracts cell location, volume, and persistence metrics across time points
- Seamless integration with existing clinical trial workflows and imaging infrastructure, requiring no specialized hardware
- Multi‑site compatibility allowing consistent data acquisition and analysis across geographically distributed study locations
- Support for a range of cell modalities, including CAR‑T, NK, and stem cell products, with optional dual‑modality imaging extensions
- Cloud‑based analytics dashboard delivering visualizations, longitudinal plots, and exportable reports for regulatory and scientific review